1. Home
  2. MHH vs KPTI Comparison

MHH vs KPTI Comparison

Compare MHH & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mastech Digital Inc

MHH

Mastech Digital Inc

HOLD

Current Price

$6.93

Market Cap

88.0M

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$5.80

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHH
KPTI
Founded
1986
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.0M
94.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
MHH
KPTI
Price
$6.93
$5.80
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$22.17
AVG Volume (30 Days)
29.9K
117.3K
Earning Date
11-12-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$196,657,000.00
$142,530,000.00
Revenue This Year
N/A
$3.82
Revenue Next Year
$4.52
$3.18
P/E Ratio
N/A
N/A
Revenue Growth
1.24
N/A
52 Week Low
$6.20
$3.51
52 Week High
$16.00
$12.45

Technical Indicators

Market Signals
Indicator
MHH
KPTI
Relative Strength Index (RSI) 42.55 50.33
Support Level $7.34 $5.30
Resistance Level $8.37 $6.05
Average True Range (ATR) 0.57 0.44
MACD -0.04 0.02
Stochastic Oscillator 7.93 37.50

Price Performance

Historical Comparison
MHH
KPTI

About MHH Mastech Digital Inc

Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: